Program
brincidofovir
Also written as “Brincidofovir”, “CMX001” and “SyB V-1901”.
Its studies are mostly in Adenoviridae Infections · Cytomegalovirus Infections · Lymphoma, T-Cell · Smallpox · Kidney Diseases, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 140 open or running | phase 3since Jun 11, 2010 | Oct 23, 2008 | none ahead |
| SymBio Pharmaceuticals | 41 open or running | phase 3since Jan 20, 2026 | Aug 29, 2020 | Jan 31, 2028phase 3 · NCT07387367 |
| Emergent BioSolutions | 10 open or running | phase 1since Jun 5, 2023 | Jun 5, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Oct 23, 2008.
- Nov 12, 2010Phase 2 study in Adenovirus DiseaseJazz Pharmaceuticals · NCT01241344 · 52 enrolled · United States
- Jun 30, 2011Phase 1 study in Hepatic ImpairmentJazz Pharmaceuticals · NCT05391724 · 25 enrolled · United States
- Jan 14, 2013Phase 3 study in CMVJazz Pharmaceuticals · NCT01769170 · 452 enrolled · United States, Belgium, Canada
- Mar 12, 2014Phase 3 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT02087306 · 201 enrolled · United States
- Oct 7, 2014Phase 2 study in Ebola VirusJazz Pharmaceuticals · NCT02271347
- May 7, 20152 phase 3 studies in Cytomegalovirus InfectionsJazz Pharmaceuticals · NCT02439970, NCT02439957
- Nov 8, 2017Phase 2 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT03339401 · 29 enrolled · United States, France, Germany and more
- Apr 26, 2018Phase 2 study in Adenoviridae InfectionsJazz Pharmaceuticals · NCT03532035 · United States, Italy, Spain
- Feb 12, 2020Phase 2 study in Hemorrhagic Fever, EbolaJazz Pharmaceuticals · NCT04268966
- Aug 29, 2020SymBio Pharmaceuticals's first study: phase 1 study in Drug Drug InteractionNew to SymBio PharmaceuticalsSymBio Pharmaceuticals · NCT04542252 · 13 enrolled · Japan
- Aug 16, 2022Phase 2 study in Kidney DiseasesSymBio Pharmaceuticals · NCT05511779 · 1 enrolled · Japan
- Jun 5, 2023Emergent BioSolutions's first study: phase 1 study in SmallpoxNew to Emergent BioSolutionsEmergent BioSolutions · NCT05935917 · 44 enrolled · United States
- Dec 24, 2024Phase 2 study in RecurrenceSymBio Pharmaceuticals · NCT06761677 · 43 enrolled · China, Japan, Singapore
- Jan 20, 2026Phase 3 study in Adenoviridae InfectionsPhase 3 reachedSymBio Pharmaceuticals · NCT07387367 · 180 planned · United States, Austria, Belgium and more
Ahead
- Jan 31, 2028Primary completion: phase 3 study in Adenoviridae InfectionsSymBio Pharmaceuticals · NCT07387367
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07387367Adenoviridae Infections · United States, Austria, Belgium and more | 3 | Recruiting | SymBio Pharmaceuticals | Jan 31, 2028 | 180 |
| NCT06761677Recurrence · China, Japan, Singapore | 2 | Suspended | SymBio Pharmaceuticals | Oct 23, 2027 | 43 |
| NCT05935917Smallpox · United States | 1 | Completed | Emergent BioSolutions | Aug 14, 2023 | 44 |
| NCT05511779Kidney Diseases · Japan | 2 | Terminated | SymBio Pharmaceuticals | Apr 13, 2023 | 1 |
| NCT04542252Drug Drug Interaction · Japan | 1 | Completed | SymBio Pharmaceuticals | Dec 22, 2020 | 13 |
| NCT04268966Hemorrhagic Fever, Ebola | 2 | Withdrawn | Jazz Pharmaceuticals | Nov 2015 | 0 |
| NCT03532035Adenoviridae Infections · United States, Italy, Spain | 2 | Withdrawn | Jazz Pharmaceuticals | May 10, 2019 | 0 |
| NCT03339401Adenoviridae Infections · United States, France, Germany and more | 2 | Terminated | Jazz Pharmaceuticals | May 10, 2019 | 29 |
| NCT02439970Cytomegalovirus Infections · United States | 3 | Terminated | Jazz Pharmaceuticals | Jan 30, 2016 | 5 |
| NCT02439957Cytomegalovirus Infections · United States | 3 | Terminated | Jazz Pharmaceuticals | May 15, 2016 | 6 |
| NCT02271347Ebola Virus | 2 | Withdrawn | Jazz Pharmaceuticals | Jan 2015 | 0 |
| NCT02087306Adenoviridae Infections · United States | 3 | Completed | Jazz Pharmaceuticals | Jun 2016 | 201 |
| NCT01769170CMV · United States, Belgium, Canada | 3 | Completed | Jazz Pharmaceuticals | Dec 2015 | 452 |
| NCT05391724Hepatic Impairment · United States | 1 | Completed | Jazz Pharmaceuticals | Sep 2011 | 25 |
| NCT01241344Adenovirus Disease · United States | 2 | Completed | Jazz Pharmaceuticals | Jun 2013 | 52 |
| NCT01143181Adenoviridae Infections · United States | 3 | Completed | Jazz Pharmaceuticals | Dec 2012 | 210 |
| NCT00942305Cytomegalovirus Infections · United States | 2 | Completed | Jazz Pharmaceuticals | Jan 2012 | 239 |
| NCT00793598Viruria · United States | 2 | Completed | Jazz Pharmaceuticals | Oct 2010 | 29 |
| NCT00780182Healthy · United States | 1 | Completed | Jazz Pharmaceuticals | Dec 2008 | 24 |
How it is read
Names in the registry
- “Brincidofovir”, 15 entries
- “CMX001”, 3 entries
- “SyB V-1901”, 1 entry
Conditions, from the studies’ own filings
- Adenoviridae Infections, 5 studies
- Cytomegalovirus Infections, 3 studies
- Lymphoma, T-Cell, 1 study
- Smallpox, 1 study
- Kidney Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.